S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Laser breakthrough could send stock soaring 2,467% (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Laser breakthrough could send stock soaring 2,467% (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The single greatest medical breakthrough of all time? (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Laser breakthrough could send stock soaring 2,467% (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Laser breakthrough could send stock soaring 2,467% (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The single greatest medical breakthrough of all time? (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Laser breakthrough could send stock soaring 2,467% (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Laser breakthrough could send stock soaring 2,467% (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The single greatest medical breakthrough of all time? (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Laser breakthrough could send stock soaring 2,467% (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Laser breakthrough could send stock soaring 2,467% (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
The single greatest medical breakthrough of all time? (Ad)
Persistent inflation, higher interest rates will weigh on global economy, OECD predicts
Sprinklr Gets Targets Raised By Analysts, Here's Why
NASDAQ:VIR

Vir Biotechnology (VIR) Stock Forecast, Price & News

$25.90
-0.14 (-0.54%)
(As of 06/7/2023 ET)
Compare
Today's Range
$25.63
$26.42
50-Day Range
$23.00
$27.29
52-Week Range
$18.05
$31.78
Volume
587,726 shs
Average Volume
932,168 shs
Market Capitalization
$3.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.75

Vir Biotechnology MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
92.1% Upside
$49.75 Price Target
Short Interest
Bearish
6.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.20mentions of Vir Biotechnology in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$23.30 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.80) to ($4.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

712th out of 981 stocks

Biological Products, Except Diagnostic Industry

114th out of 159 stocks


VIR stock logo

About Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

VIR Stock News Headlines

This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down to $26.67
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
Vir Biotechnology (NASDAQ: VIR)
See More Headlines

VIR Price History

VIR Company Calendar

Last Earnings
5/04/2023
Today
6/07/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VIR
Fax
N/A
Employees
444
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.75
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+92.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$515.84 million
Pretax Margin
-69.64%

Debt

Sales & Book Value

Annual Sales
$1.62 billion
Cash Flow
$3.75 per share
Book Value
$15.61 per share

Miscellaneous

Free Float
109,727,000
Market Cap
$3.47 billion
Optionable
Optionable
Beta
0.26

Key Executives

  • Dr. George A. Scangos Ph.D. (Age 75)
    Pres, CEO & Director
    Comp: $1.07M
  • Mr. Howard HornMr. Howard Horn (Age 45)
    Exec. VP, CFO & Sec.
    Comp: $732.41k
  • Dr. Ann M. Hanly Ph.D. (Age 53)
    Exec. VP & Chief Technology Officer
    Comp: $922.22k
  • Dr. Phillip Pang M.D. (Age 48)
    Ph.D., Exec. VP, Chief Medical Officer & Interim Head of Research
    Comp: $780.46k
  • Dr. Klaus Frueh Ph.D. (Age 63)
    Co-Founder & Scientific Advisor
  • Dr. Lawrence Corey M.D.
    Co-Founder & Scientific Advisor
  • Dr. Louis J. Picker M.D.
    Co-Founder & Scientific Advisor
  • Ms. Johanna Friedl-Naderer (Age 55)
    Exec. VP & COO
  • Mr. Steven J. RiceMr. Steven J. Rice (Age 63)
    Exec. VP & Chief Admin. Officer
  • Ms. Heather Rowe Armstrong
    VP of Investor Relations













VIR Stock - Frequently Asked Questions

Should I buy or sell Vir Biotechnology stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VIR shares.
View VIR analyst ratings
or view top-rated stocks.

What is Vir Biotechnology's stock price forecast for 2023?

6 equities research analysts have issued 1 year price objectives for Vir Biotechnology's shares. Their VIR share price forecasts range from $27.00 to $100.00. On average, they predict the company's stock price to reach $49.75 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price.
View analysts price targets for VIR
or view top-rated stocks among Wall Street analysts.

How have VIR shares performed in 2023?

Vir Biotechnology's stock was trading at $25.31 on January 1st, 2023. Since then, VIR stock has increased by 2.3% and is now trading at $25.90.
View the best growth stocks for 2023 here
.

When is Vir Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VIR earnings forecast
.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.20. The business earned $63 million during the quarter, compared to the consensus estimate of $50.10 million. The company's revenue was down 94.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.93 earnings per share.

What is George Scangos' approval rating as Vir Biotechnology's CEO?

7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees.

When did Vir Biotechnology IPO?

(VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

What is Vir Biotechnology's stock symbol?

Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR."

Who are Vir Biotechnology's major shareholders?

Vir Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include SB Investment Advisers UK Ltd. (13.67%), BlackRock Inc. (10.42%), Temasek Holdings Private Ltd (4.34%), State Street Corp (4.02%), Baillie Gifford & Co. (2.98%) and Geode Capital Management LLC (1.14%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Jay Parrish, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vir Biotechnology's stock price today?

One share of VIR stock can currently be purchased for approximately $25.90.

How much money does Vir Biotechnology make?

Vir Biotechnology (NASDAQ:VIR) has a market capitalization of $3.47 billion and generates $1.62 billion in revenue each year. The company earns $515.84 million in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Vir Biotechnology have?

The company employs 444 workers across the globe.

How can I contact Vir Biotechnology?

Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The official website for the company is www.vir.bio. The company can be reached via phone at 415-906-4324 or via email at ir@vir.bio.

This page (NASDAQ:VIR) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -